Blanco M T, Hurtado C, Pérez-Giraldo C, Morán F J, González-Velasco C, Gómez-García A C
Department of Microbiology, Faculty of Medicine, University of Extremadura, Badajoz, Spain.
Med Mycol. 2003 Apr;41(2):167-70. doi: 10.1080/mmy.41.2.167.170.
An in vitro study to evaluate the antifungal effect and activity of aspartyl proteinases of the HIV-proteinase inhibitors ritonavir and saquinavir was conducted. Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg l(-1) of ritonavir a partial growth inhibition (44%) was produced. The growth rate of C. albicans in medium with saquinavir was similar to that seen in the control, and Sap activity was inhibited only at high concentrations. In conventional medium (RPMI-1640), which does not induce the production of yeast proteases, no inhibitory effect was detected with either HIV-protease inhibitor.
开展了一项体外研究,以评估HIV蛋白酶抑制剂利托那韦和沙奎那韦的天冬氨酸蛋白酶的抗真菌作用及活性。在氮限制培养基、酵母碳源和牛血清白蛋白(YCB-BSA)中,利托那韦降低了白色念珠菌的生长速率及其分泌的天冬氨酸蛋白酶(Saps)的活性。这种抑制呈剂量依赖性;8 mg l(-1)的利托那韦产生了部分生长抑制(44%)。在含有沙奎那韦的培养基中,白色念珠菌的生长速率与对照相似,且仅在高浓度时Sap活性受到抑制。在不诱导酵母蛋白酶产生的传统培养基(RPMI-1640)中,未检测到这两种HIV蛋白酶抑制剂有抑制作用。